New GSK leukemia drug shows promise after trial
Scientists believe a new drug developed by British pharmaceutical company GlaxoSmithKline (GSK) could have the potential to effectively treat mixed-lineage leukemia (MLL).
MLL is the most common strain of leukemia to affect babies and children and it is estimated 80 percent of under two-year-olds who receive a diagnosis for leukemia are affected with the strain.
The researchers from GSK worked in conjunction with the biggest cancer charity in the world - Cancer Research UK – and found the experimental I-BET151 drug prevents leukemia genes from being activated.
It is thought babies and children develop MLL when a mixed-lineage gene fuses to another gene, the result of which is the production of a ‘fusion protein’ which turns on cancer genes.
To read the latest edition of Healthcare Global, click here
- Healthcare cuts will increase medical tourism
- New Health Lottery to earn £50 million for healthcare services
- Cosmetic surgery promo gives boob jobs as raffle prizes
The results of the research into GSK’s new drug have been published in the journal Nature and it is now hoped the next step in the research process will be patient trials.
Lesley Walker, the Director of Information at Cancer Research UK commented: “We urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL.
“Although this research is only in the lab at the moment, we hope it will move quickly toward clinical trials in patients.”
If the drug performs well in future tests, it could bring new hope to those living with leukemia as although there are currently treatments available for the disease, most patients do not respond well to them and the cancer often returns.
Our magazine is now available on the iPad. Click here to download it.
Dubai's new smart neuro spinal hospital: need to know
We take a look at Dubai's new smart hospital.
What: The Neuro Spinal Hospital and Radiosurgery Centre is a new hospital featuring state-of-the-art technology for spinal, neurosurgical, neurological, orthopaedic, radiosurgery and cancer treatments. The 700 million AED hospital, (equivalent to £138 million), has 114 beds, smart patient rooms, and green spaces for patient rehabilitation, and is four times the capacity of its former premises in Jumeirah. It is also the UAE’s first hospital to have surgical robots.
Where: The hospital is located in the Dubai Science Park. Founded in 2005, Dubai Science Park is home to more than 350 companies from multinational corporations in life sciences, biotechnology and research; over 4,000 people work here each day.
Who: The UAE's Neuro Spinal Hospital and Radiosurgery Centre was first established in Jumeirah in 2002 by Dr. Abdul Karim Msaddi, as the first as the first "super-specialty" neuroscience hospital.
Why: With advanced diagnosis and robotics, the hospital will provide care across neuroscience, spine, orthopaedics and oncology for people residing in the UAE, as well as international patients.
Prof. Abdul Karim Msaddi, Chairman and Medical Director of the hospital, said: “We are proud to bring world-class healthcare services to Dubai and believe our next-generation hospital will be a game-changer for the emirate’s and the region’s medical industry.
"It will not only significantly increase the availability of specialist neuroscience and radiosurgery treatments and provide better patient care but help attract and develop local and international talent. Investing in the new centre represents our continued faith in the resilience of the region’s economy, as well as a testament to our ongoing drive towards healthcare innovation in the UAE.”